Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Justin Watts, Uma Borate, Mark Levis, Yasmin Abaza, Eunice Wang, Joshua Zeidner, Hongliang Cai, Bo Xu, Priya Robson, Akinobu Watanabe, Matthew Hitron, Jatin Shah, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 765.

https://doi.org/10.1182/blood-2025-765

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Katarina Micin, Ellen Madarang, Tiffany Nong, Maurizio Affer, Kiana Robles, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin Watts, Justin Taylor

Blood (2025) 146 (Supplement 1): 280.

https://doi.org/10.1182/blood-2025-280

Published: 2025

Journal Articles

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

Mina Tayari, Tulasigeri Totiger, Felipe Beckedorff, Adnan Mookhtiar, Anna Lesley Kingham, Gloria Mas Martin, Hsuan-Ting Huang, Efe Karaca, Daniel Bilbao, Justin Taylor, Ramin Shiekhattar, Justin Watts

Blood (2025) 146 (Supplement 1): 3292.

https://doi.org/10.1182/blood-2025-3292

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Jay Yang, Joseph Jurcic, Christian Recher, Pierre Fenaux, Andrew Wei, Antonio Curti, Justin Watts, Eunice Wang, Brian Jonas, Jorge Cortes, Aaron Sheppard, Sophia Wang, Stephane De Botton

Blood (2025) 146 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2025-5213

Published: 2025

Journal Articles

A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy

Justin Watts, Gautam Borthakur, Tara Lin, Nashat Gabrail, Kruti Patel, Yazan Madanat, Joshua Zeidner, Noor Khaskhely, Lynn Bonham, Michelle Nelson, John Kumer, Daphne Taylor, Caroline Taromino, Miriam Weber Miller, Dirk Huebner, Michael Maris

Blood (2025) 146 (Supplement 1): 5198.

https://doi.org/10.1182/blood-2025-5198

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy

Justin Watts, Brittany Ragon, Namrata Chandhok, Mikkael Sekeres, Sangeetha Venugopal, Amanda Johnston, Mirla Langlois, Nicole DeFord, John Bomalaski, Naveen Pemmaraju, Nitin Jain, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1650.

https://doi.org/10.1182/blood-2025-1650

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

Justin Watts, Eunice Wang, Brian Jonas, William Donnellan, Jay Yang, Karen Seiter, Andrew Wei, Stephane De Botton, Amber Thomassen, Hua Tian, Jorge Cortes

Blood (2025) 146 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2025-1659

Published: 2025

Journal Articles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie, Gabriel Mannis, Justin Watts, Farhad Ravandi, Gary Schiller, Brian Ball, Hongtao Liu, Jessica Altman, Eunice Wang, J. Jean Cui, Jihao Zhou, Zachary Zimmerman, Stephen Strickland

Blood (2025) 146 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2025-1655

Published: 2025

Journal Articles

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Blood (2023) 141 (19): 2359–2371.

https://doi.org/10.1182/blood.2022018244

Published: 2023

Includes: Supplemental data

Journal Articles

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Justin Watts, Anthony M. Hunter, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Brandi Reeves, Alessandro M. Vannucchi, Xuejun Chen, Francis Seguy, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2022) 140 (Supplement 1): 9696–9697.

https://doi.org/10.1182/blood-2022-169740

Published: 2022

Journal Articles

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims

Blood (2022) 140 (Supplement 1): 6204–6205.

https://doi.org/10.1182/blood-2022-167468

Published: 2022

Journal Articles

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Jan Philipp Bewersdorf, Maximilian F. Stahl, Justin Taylor, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Victoria Kostantakis, Sydney X. Lu, Jessie Bourcier, Simon Hogg, Tulasigeri M Totiger, Omar Abdel-Wahab, Eytan Stein

Blood (2022) 140 (Supplement 1): 9065–9067.

https://doi.org/10.1182/blood-2022-156830

Published: 2022

Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda

Blood (2022) 140 (Supplement 1): 3371–3372.

https://doi.org/10.1182/blood-2022-167674

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only